乙酰肝素酶mRNA在乳腺癌中的表达及其与乳腺癌病理特征的关系

Expression of heparitinase mRNA in breast carcinoma and relationship between it and the pathological features of breast carcinoma

目的探讨乙酰肝素酶(HPA)mRNA在乳腺癌组织中的表达及其与乳腺癌病理特征的关系。方法应用原位杂交技术检测HPA mRNA在乳腺癌组织及50例相应癌旁正常乳腺组织中的表达,免疫组织化学染色检测50例乳腺癌组织中CD34表达情况,并分析HPA mRNA表达与乳腺癌浸润、转移及微血管密度(MVD)的相关性。结果乳腺癌组织和正常乳腺组织中HPA mRNA阳性表达率分别为70.0%(35/50)和24.0%(12/50),乳腺癌组织中HPA mRNA阳性表达率显著高于正常乳腺组织(P<0.01)。HPA mRNA表达与乳腺癌组织学分级、淋巴结转移及肿瘤侵袭程度有相关性(P<0.05,P<0.01)。35例HPA mRNA阳性患者的MVD为58.20±18.56,15例HPA mRNA阴性患者的MVD为41.30±9.35,HPA mRNA阳性患者MVD显著高于HPA mRNA阴性患者(P<0.01)。结论 HPA与乳腺癌的浸润、转移及血管生成有重要关系,可作为评估乳腺癌生物学行为的客观指标。

Objective To investigate the expression of heparitinse（ HPA） mRNA in breast carcinoma and the relationship between HPA and the pathological features of breast carcinoma. Methods The expression of HPA mRNA in 50 cases of breast carcinoma tissues and 50 cases of adjacent normal breast tissues was detected by hybridization in situ method. The expression of CD34 in patients with breast carcinoma tissues was detected by immunohistostaining. The relationship between the expression of HPA mRNA and invasion,metastasis,microvessel density（ MVD） of breast carcinoma was analyzed. Results The positive rate of HPA mRNA in breast carcinoma tissues and normal breast tissues was 70. 0%（ 35 /50） and 24. 0%（ 12 /50） respectively,the positive rate of HPA mRNA in breast carcinoma tissues was significantly higher than that in normal breast tissues（ P〈0. 01）. The expression of HPA mRNA was correlated to histological grading,lymphaden metastasis and invasiveness of breast carcinoma（ P〈0. 05,P〈0. 01）. The MVD in 35 cases of positive HPA mRNA expression was 58. 20 ±18. 56,it was 41. 30 ± 9. 35 in 15 cases of negative HPA mRNA expression,the MVD in patients with positive expression of HPA mRNA was significantly higher than that in patients with negative expression of HPA mRNA（ P〈0. 01）. Conclusion HPA is correlated to invasion,metastasis and vascularization. HPA can be used as a objective index for evaluating the biological behaviour of breast carcinoma.